AREA[OverallStatus] Lymphoproliferative Disorders, Open or Pending: 2661 Clinical Trials, Page 1 of 267

1 2 3 4 5 10 15 20  Last Page »

Include Studies Not Open or Pending

9

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Condition(s):Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Solid Organ Transplant Complications; Lymphoproliferative Disorders; Allogeneic Hematopoietic Cell Transplant; Stem Cell Transplant ComplicationsLast Updated:June 24, 2022Recruiting

1 2 3 4 5 10 15 20  Last Page »

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.